Eli Lilly and Company

Eli Lilly and Company traces its origins to 1876, when Union Army veteran Eli Lilly founded the firm in Indianapolis to manufacture quinine and morphine. The company has since expanded into a global pharmaceutical leader operating offices in 36 countries while distributing treatments across nearly 90 nations. In November 2025, it became the first healthcare company to reach a $1 trillion market capitalization, surpassing competitors like Novo Nordisk and Johnson & Johnson.

Financial performance in 2025 relied heavily on tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. This single product line generated 56% of total revenues that year. Other significant portfolio items include Verzenio for breast cancer, Trulicity for diabetes management, Taltz for autoimmune diseases, and Jardiance for blood sugar control. While the firm produces generic versions of legacy drugs like Prozac and Cymbalta, current valuation depends on pioneering new therapies for chronic conditions.

Leadership transitions have marked recent years with David A. Ricks succeeding John C. Lechleiter after over two decades of service. Previous CEOs Sidney Taurel and Randall L. Tobias also shaped the modern strategic direction. As of late October 2026, stock prices reached approximately $1,311 per share, pushing the company's valuation past Berkshire Hathaway ahead of Q3 earnings reports. [edit]